Betulin and Gamma-Cyclodextrin Composition for Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are ineffective and lack a specific target for combating the disease, with existing drugs showing minimal efficacy, and there is a need for a more effective adjuvant therapy to enhance, boost, restore, and prevent cognitive decline.
Innovation Solution
A composition comprising betulin and γ-cyclodextrin, administered in specific ratios, is used to enhance, boost, and prevent cognitive decline, potentially as a dietary supplement, and is designed to be used in conjunction with subeffective doses of anti-AD medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-AD medications are used, then treatment for Alzheimer's disease is provided, but efficacy is minimal and cognitive decline continues
Solution Approach 1:
The patent combines betulin (a natural compound) with γ-cyclodextrin (a solubilizing agent) to create a composite composition that enhances the delivery and efficacy of betulin. This composite approach addresses the low efficacy of current treatments by using a synergistic combination rather than a single substance, improving both reliability and cognitive function maintenance.
Solution Approach 2:
The patent specifies precise dosage ranges (100-250 mg betulin and 580-1465 mg γ-cyclodextrin) to optimize therapeutic effect while minimizing side effects. By carefully controlling the parameters of composition and dosage, the treatment achieves improved efficacy compared to current medications without causing significant adverse effects.
2Reliability
If higher doses of current medications are administered, then more aggressive treatment is provided, but side effects increase and efficacy does not improve significantly
Solution Approach 1:
γ-Cyclodextrin acts as an intermediary substance that enhances the solubility and bioavailability of betulin, allowing for effective treatment at lower doses. This mediator enables the active compound to be delivered more efficiently to the target site, improving effectiveness without requiring higher doses that would increase side effects.
Solution Approach 2:
The patent uses subeffective doses of conventional anti-AD medications in combination with the betulin composition. This partial action approach acknowledges that current medications alone are insufficient, but by combining them with the natural compound composition at optimized doses, the overall effectiveness is enhanced without the need to increase doses of medications that cause side effects.
3Object-affected harmful factors
If no treatment is provided, then side effects are avoided, but cognitive decline progresses unchecked
Solution Approach 1:
The patent utilizes betulin, a naturally occurring compound that can be sourced from renewable plant materials (birch bark, pine bark). This natural, readily available substance provides therapeutic benefit without the long-term accumulation and severe side effects associated with conventional synthetic anti-AD medications, allowing for repeated administration to preserve cognitive function.
Solution Approach 2:
The composition specifies optimized dosage ranges that maximize therapeutic benefit while minimizing adverse effects. By carefully controlling the parameters of betulin and γ-cyclodextrin dosages, the treatment achieves cognitive protection without causing significant side effects, unlike untreated progression or conventional medication regimens.
Data Source
AI summary
A composition includes from 100 mg to 250 mg of betulin and from 580 mg to 1465 mg of γ (gamma)-cyclodextrin for use in at least one of enhancing, boosting, restoring or preventing the decline of cognitive functions. An adjuvant composition, a method of using the composition or adjuvant composition and a kit including the composition or adjuvant composition, are also provided.